Loading...
XLON
SN.
Market cap14bUSD
Mar 24, Last price  
1,239.16GBP
Name

Smith & Nephew PLC

Chart & Performance

D1W1MN
XLON:SN. chart
P/E
35.01
P/S
2.48
EPS
0.47
Div Yield, %
Shrs. gr., 5y
14.86%
Rev. gr., 5y
2.49%
Revenues
5.81b
+4.70%
2,552,000,0002,779,000,0003,369,000,0003,801,000,0003,772,000,0003,962,000,0004,270,000,0004,137,000,0004,351,000,0004,617,000,0004,634,000,0004,669,000,0004,765,000,0004,904,000,0005,138,000,0004,560,000,0005,212,000,0005,215,000,0005,549,000,0005,810,000,000
Net income
412m
+56.65%
333,000,000745,000,000316,000,000377,000,000472,000,000615,000,000582,000,000729,000,000556,000,000501,000,000410,000,000784,000,000767,000,000663,000,000600,000,000448,000,000524,000,000223,000,000263,000,000412,000,000
CFO
987m
+62.34%
260,000,000352,000,000424,000,000566,000,000719,000,000859,000,000842,000,000902,000,000867,000,000683,000,0001,030,000,000849,000,0001,090,000,000931,000,0001,168,000,000935,000,000877,000,000468,000,000608,000,000987,000,000
Dividend
Apr 02, 20200.1866 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
IPO date
Aug 13, 1951
Employees
19,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT